Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UHK6
UPID:
AMACR_HUMAN
Alternative names:
2-methylacyl-CoA racemase
Alternative UPACC:
Q9UHK6; A5YM47; B8Y916; B8Y918; F8W9N1; O43673; Q3KT79; Q96GH1; Q9Y3Q1
Background:
Alpha-methylacyl-CoA racemase, also known as 2-methylacyl-CoA racemase, plays a crucial role in the metabolism of fatty acids, facilitating the conversion of (R)- and (S)-stereoisomers of alpha-methyl-branched-chain fatty acyl-CoA esters. This enzyme's activity is pivotal in processing a variety of substrates, including pristanoyl-CoA and trihydroxycoprostanoyl-CoA, essential in bile acid synthesis.
Therapeutic significance:
The enzyme's dysfunction is linked to Alpha-methylacyl-CoA racemase deficiency and Congenital bile acid synthesis defect 4, diseases characterized by neurodegenerative symptoms and cholestasis, respectively. Understanding the role of Alpha-methylacyl-CoA racemase could open doors to potential therapeutic strategies for these conditions.